Crestline Management LP Raises Stock Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Crestline Management LP increased its position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 114.0% in the 4th quarter, HoldingsChannel.com reports. The firm owned 295,354 shares of the biopharmaceutical company’s stock after acquiring an additional 157,366 shares during the period. Crestline Management LP’s holdings in Celldex Therapeutics were worth $7,464,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Vanguard Group Inc. grew its stake in Celldex Therapeutics by 0.3% in the 4th quarter. Vanguard Group Inc. now owns 3,881,995 shares of the biopharmaceutical company’s stock valued at $98,098,000 after acquiring an additional 12,213 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Celldex Therapeutics by 23.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,557,136 shares of the biopharmaceutical company’s stock worth $89,890,000 after purchasing an additional 676,771 shares in the last quarter. Rock Springs Capital Management LP raised its position in shares of Celldex Therapeutics by 10.7% during the 4th quarter. Rock Springs Capital Management LP now owns 1,222,182 shares of the biopharmaceutical company’s stock worth $30,885,000 after purchasing an additional 118,404 shares during the last quarter. Novo Holdings A S lifted its stake in Celldex Therapeutics by 3.8% in the 4th quarter. Novo Holdings A S now owns 1,000,000 shares of the biopharmaceutical company’s stock valued at $25,270,000 after buying an additional 36,337 shares in the last quarter. Finally, Eversept Partners LP grew its holdings in Celldex Therapeutics by 27.4% during the 4th quarter. Eversept Partners LP now owns 719,836 shares of the biopharmaceutical company’s stock valued at $18,190,000 after buying an additional 154,934 shares during the last quarter.

Celldex Therapeutics Trading Down 1.8 %

Shares of CLDX opened at $20.29 on Tuesday. The stock’s fifty day simple moving average is $19.09 and its 200 day simple moving average is $23.07. Celldex Therapeutics, Inc. has a twelve month low of $14.40 and a twelve month high of $47.00. The firm has a market capitalization of $1.35 billion, a P/E ratio of -7.89 and a beta of 1.39.

Celldex Therapeutics (NASDAQ:CLDX) last issued its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.02. The business had revenue of $1.18 million during the quarter, compared to analysts’ expectations of $1.25 million. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. Sell-side analysts predict that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current year.

Analyst Upgrades and Downgrades

CLDX has been the topic of several recent research reports. UBS Group initiated coverage on Celldex Therapeutics in a research report on Thursday, February 13th. They issued a “buy” rating and a $44.00 price objective on the stock. The Goldman Sachs Group lowered their price target on shares of Celldex Therapeutics from $42.00 to $36.00 and set a “neutral” rating for the company in a report on Monday, March 3rd. Cantor Fitzgerald restated an “overweight” rating and set a $67.00 target price on shares of Celldex Therapeutics in a research report on Wednesday, January 29th. Morgan Stanley assumed coverage on shares of Celldex Therapeutics in a research note on Thursday, March 20th. They issued an “overweight” rating and a $46.00 target price for the company. Finally, Canaccord Genuity Group assumed coverage on Celldex Therapeutics in a research note on Monday, April 28th. They set a “buy” rating and a $64.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $55.30.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.